Is Acer Therapeutics efficiently growing its dividend?
Acer Therapeutics does not have a long track record of dividend growth. In the past three months, Acer Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,334.00 in company stock and sold $0.00 in company stock.
Where can I buy Acer shares?
Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is Acer therapeutics using insider ownership a sign of company health?
A high percentage of insider ownership can be a sign of company health. Only 10.93% of the stock of Acer Therapeutics is held by institutions. Earnings for Acer Therapeutics are expected to decrease in the coming year, from ($1.02) to ($1.39) per share.
What is Acer therapeutics'market capitalization?
Acer Therapeutics has a market capitalization of $33.77 million. The biopharmaceutical company earns $-22.89 million in net income (profit) each year or ($1.07) on an earnings per share basis. How many employees does Acer Therapeutics have? Acer Therapeutics employs 2,018 workers across the globe. What is Acer Therapeutics' official website?
See more
Where is Acer located?
What is the 6th largest PC vendor?
Acer Inc. is a Taiwanese multinational hardware and electronics corporation specializing in advanced electronics technology, headquartered in Xizhi, New Taipei City.
How much revenue did Acer make in 2021?
Acer is the world's 6th-largest PC vendor by unit sales as of January 2021. In the early 2000s, Acer implemented a new business model, shifting from a manufacturer to a designer, marketer, and distributor of products, while performing production processes via contract manufacturers.
What is Acer 001?
Acer recognized revenue of $4.0 million during the three months ended March 31, 2021, related to the license of intellectual property as part of the Collaboration Agreement signed during the quarter. Research and Development Expenses.
Is Acer a NDA?
ACER-001 is a proprietary immediate release multi-particulate powder formulation of sodium phenylbutyrate (NaPB) with a taste-masked coating. ACER-001 is being developed in collaboration with Relief. The purpose of the pre-NDA meeting was to discuss the content of Acer’s planned NDA submission.
When did Acer release its earnings?
The stock price moved after the pharmaceutical company and its collaboration partner, Relief Therapeutics Holding SA, received the U.S. Food and Drug Administration’s (FDA) green light to file the New Drug Application (NDA) for ACER-001. ACER-001 (sodium phenylbutyrate) is designed for the treatment of patients with various inborn errors of metabol
What is the Acer Therapeutics ticker symbol?
Acer Therapeutics Inc. (NASDAQ:ACER) released its earnings results on Sunday, May, 16th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.33.
How much does Acer Therapeutics make?
Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."
What is the P/E ratio of Acer Therapeutics?
Acer Therapeutics has a market capitalization of $35.78 million. The biopharmaceutical company earns $-22,890,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.
What is Acer Therapeutics?
The P/E ratio of Acer Therapeutics is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Does Acer Therapeutics pay dividends?
Acer Therapeutics, Inc. is a pharmaceutical company. It engages in the acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded on March 15, 1991 and is headquartered in Newton, MA.
